Company Profile (AI Text)
Name: Neopenda
Canonical URL: https://wefunder.com/neopenda
Updated at: 2026-06-09T05:01:10Z

Tagline: Life-saving technology for the world's most vulnerable newborns

Key claims:
- Total raised on Wefunder: 272235 | citation: https://wefunder.com/neopenda#claim-total-raised
- Total investors: 224 | citation: https://wefunder.com/neopenda#claim-total-investors

Verified facts:
- Total raised on Wefunder: 272235 | observed_at: 2026-06-09T05:01:10Z | expires_at: 2026-06-10T05:01:10Z
- Total investors: 224 | observed_at: 2026-06-09T05:01:10Z | expires_at: 2026-06-10T05:01:10Z

Computed metrics:
- total_amount_raised: 272235
- total_investors: 224
- team_size: 5
- featured_investor_count: 1
- faq_count: 5
- recent_post_count: 0

Quick facts:
- 150,000+ monitoring hours across 50+ hospitals, 5,000+ newborns no longer left unseen | citation: https://wefunder.com/neopenda#claim-fact-1
- 53% YoY sales growth in Kenya | citation: https://wefunder.com/neopenda#claim-fact-2
- $6M+ from Fortune 500s, global health foundations, and top accelerators including Techstars | citation: https://wefunder.com/neopenda#claim-fact-3
- Patented, CE-marked, ISO 13485 certified, a validated commercial product | citation: https://wefunder.com/neopenda#claim-fact-4
- Built by Columbia-trained biomedical engineers with Medtronic, GSK, and Eli Lilly team experience | citation: https://wefunder.com/neopenda#claim-fact-5
- Qualified by WHO andUNITAID as a breakthrough technology for low-resource settings | citation: https://wefunder.com/neopenda#claim-fact-6

FAQ:
- Q: Is your target market limited to Africa for the time being? Will the majority of your employees eventually be people living in Africa, including managers? Do you have many competitors or potential competitors?
  A: Thanks for the thoughtful question! Our current focus is on Africa as it’s one of the largest untapped markets for healthcare innovation with a global neonatal mortality burden and a critical shortage of clinical tools. That said, the challenges we’re solving exist in 85% of emerging markets globally, and we’ve already begun piloting in other strategic countries beyond Africa. As we grow, our hiring philosophy is simple, hire first in Africa unless there’s a specific reason not to, such as ti...
- Q: Hi Sona, are you looking out for app development team to build out the app
  A: Hi Majed, thanks for your question! We have an in-house team that has built out our existing android app, and will continue to build out future apps.
- Q: Hey, How can I reach the founder to discuss company regarding investing?
  A: Hi Yaacov- happy to chat. Feel free to email me at sona@neopenda.com.
- Q: 1) How will you make money ? 2) Is a working piece deployed ? 3) Any revenue info and cost per unit info ?
  A: Thanks for your question! We sell neoGuard in packages of 5–15 devices to public and private hospitals, as well as through channel partners such as county governments, Ministries of Health, NGOs, and distributors. To date, we've deployed over 400 devices across 45+ facilities, with 40%+ margins on each package sold and a clear path to expand to 70% margins through local production on the African continent.
- Q: Hello 1 vital signs monitoring is not really a strong IP. Can be easily copied w existing sensors. 2 The money is in the US market and you are totally absent. 3 This started in 2016 now nearly 10 years later you are still on the runway. My investment most likely will never see...
  A: We appreciate your perspective and the opportunity to clarify a few important points. First, our vital signs monitor, neoGuard, is protected by patents in the US and several other countries, covering the unique design and application of our technology in low-resource settings. While the underlying sensors may be available, our innovation lies in how we’ve integrated them into a clinically validated, low-power, modular solution tailored for environments where traditional monitors fail. That’s ...